Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.45 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533549 | 0.91 | SMPD3 (0.50) | PI4KBSMPD3MEN1KMT2AATM | |
| SCHEMBL20534224 | 0.88 | SMPD3 (0.45) | PI4KBSMPD3MEN1KMT2AATM | |
| SCHEMBL20533928 | 0.86 | PI4KB (0.48) | PI4KBMEN1KMT2AATMMAPT | |
| SCHEMBL20533915 | 0.86 | PI4KB (0.45) | PI4KBSMPD3MEN1KMT2AATM | |
| SCHEMBL20533595 | 0.85 | PI4KB (0.61) | PI4KBSMPD3MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20534222 | 0.85 | PI4KB (0.45) | PI4KBMEN1KMT2AATMMAPT | |
| SCHEMBL20534146 | 0.84 | SMPD3 (0.40) | PI4KBSMPD3MEN1KMT2AATM | |
| SCHEMBL20533594 | 0.83 | ALDH1A1 (0.36) | PI4KBSMPD3MAPTHSD17B10LMNA | |
| SCHEMBL20533747 | 0.80 | PI4KB (0.63) | PI4KBSMPD3MEN1KMT2AATM | |
| SCHEMBL20533904 | 0.79 | PI4KB (0.60) | PI4KBMEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | PI4KB 3/4885SMPD3 2463/4885MEN1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.